Aptorum Group Limited (APM)
| Market Cap | 104.42M |
| Revenue (ttm) | 535,166 |
| Net Income (ttm) | -18.69M |
| Shares Out | 29.01M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $3.07 |
| Previous Close | $3.19 |
| Change ($) | -0.12 |
| Change (%) | -3.76% |
| Day's Open | 3.16 |
| Day's Range | 3.03 - 3.36 |
| Day's Volume | 449,833 |
| 52-Week Range | 1.16 - 14.23 |
Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical compa...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biop...
Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?
Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.
APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy...
APM stock remains a highly speculative bet for investors as the small biotech company comes with significant risk and volatility. The post Aptorum Group Is Risky, Despite Popularity appeared f...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biop...
APM stock mostly flew under the radar among biotechnology investors. After a recent price surge, though, the stock is now an attention getter.
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on n...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical com...
Aptorum Group Ltd. (NASDAQ: APM) shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious di...
Aptorum Group Ltd (NASDAQ: APM) shares are skyrocketing Tuesday following an announcement concerning the setting up of a subsidiary focused on diagnostic testing. What Happened: U.K.-based ...
APM stock is soaring on news that Aptorum Group is launching a subsidiary focused on liquid biopsies for infectious diseases. The post APM Stock: Why Aptorum Group Is Soaring 500% Today appea...
NEW YORK, LONDON, & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical...
NEW YORK--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address gl...
NEW YORK--(BUSINESS WIRE)-- #euronextlisting--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeuti...
NEW YORK--(BUSINESS WIRE)-- #Euronext--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to a...
About APM
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in n... [Read more...]
| Industry Biotechnology | IPO Date Dec 18, 2018 |
| CEO Chung Yuen Huen | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol APM |
Financial Performance
In 2019, Aptorum Group's revenue was $535,166, an increase of 39.57% compared to the previous year's $383,450. Losses were -$18.69 million, 26.0% more than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for Aptorum Group stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 323.45% from the latest price.